HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Scope & Guideline

Bridging Research and Clinical Excellence

Introduction

Delve into the academic richness of HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0889-8588
PublisherW B SAUNDERS CO-ELSEVIER INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1987 to 2024
AbbreviationHEMATOL ONCOL CLIN N / Hematol. Oncol. Clin. North Am.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899

Aims and Scopes

The journal 'Hematology-Oncology Clinics of North America' aims to provide a comprehensive platform for the latest advancements in hematology and oncology, focusing on the clinical aspects of cancer care and treatment. It encompasses a diverse range of topics that reflect the complexities of cancer treatment and research, with a strong emphasis on multidisciplinary approaches to patient management.
  1. Clinical Innovations in Cancer Treatment:
    The journal features papers on the latest advancements in cancer therapies, including immunotherapy, targeted therapies, and novel drug developments, demonstrating a commitment to improving patient outcomes.
  2. Research on Cancer Pathophysiology:
    It explores the biological mechanisms underlying various cancers, including genetic and molecular studies that inform treatment strategies and improve understanding of disease progression.
  3. Multidisciplinary Management of Cancer:
    The journal emphasizes the importance of collaboration among various specialties in the management of cancer, showcasing studies on surgical, medical, and supportive care approaches.
  4. Health Disparities in Cancer Care:
    There is a focus on addressing inequities in cancer treatment and outcomes, with research highlighting disparities based on socioeconomic status, geography, and access to care.
  5. Preventive Oncology and Early Detection:
    The journal promotes research on cancer prevention strategies, screening methods, and the identification of precursor lesions to facilitate early diagnosis and intervention.
The journal has adapted to the rapidly changing landscape of cancer research and treatment, with several emerging themes gaining traction in recent publications. This section outlines these trending areas that are likely to shape future research and clinical practice.
  1. Advancements in Immunotherapy:
    Recent publications increasingly focus on immunotherapy, particularly CAR T-cell therapy and checkpoint inhibitors, underscoring the shift towards harnessing the immune system to combat cancer.
  2. Targeted Therapies and Precision Medicine:
    There is a prominent trend towards the exploration of targeted therapies tailored to individual genetic profiles, reflecting a growing commitment to precision medicine in oncology.
  3. Biomarkers for Early Detection and Treatment Response:
    Emerging research on biomarkers for cancer detection and monitoring treatment responses is gaining importance, highlighting the need for tools that can guide clinical decision-making.
  4. Global Health and Cancer Disparities:
    The journal is increasingly addressing global health issues in oncology, focusing on disparities in cancer care and treatment outcomes, particularly in low- and middle-income countries.
  5. Integration of Technology in Cancer Care:
    Innovations in technology, such as telemedicine and digital health, are becoming more prevalent in the journal, reflecting the adaptation of cancer care delivery in an evolving healthcare landscape.

Declining or Waning

As the field of oncology evolves, certain themes within 'Hematology-Oncology Clinics of North America' appear to be diminishing in frequency or focus. This section highlights these waning areas, reflecting shifts in research priorities and clinical practice.
  1. Traditional Chemotherapy Approaches:
    With the rise of targeted therapies and immunotherapies, traditional chemotherapy regimens are receiving less emphasis in recent publications, indicating a shift towards more personalized treatment strategies.
  2. Basic Science Research Without Clinical Application:
    There is a noticeable decline in purely basic science research that lacks direct clinical relevance, as the journal increasingly prioritizes studies that translate findings into practical applications in patient care.
  3. Focus on Established Cancer Types:
    Research on well-established cancer types, such as breast and prostate cancer, is becoming less prominent as newer, less common malignancies gain attention, reflecting a broadening scope of interest within the oncology community.

Similar Journals

Frontiers in Oncology

Advancing cancer research for a healthier tomorrow.
Publisher: FRONTIERS MEDIA SAISSN: 2234-943XFrequency: 1 issue/year

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

CLINICAL ONCOLOGY

Transforming Patient Outcomes with Pioneering Oncology Studies
Publisher: ELSEVIER SCIENCE LONDONISSN: 0936-6555Frequency: 6 issues/year

Clinical Oncology is a prestigious peer-reviewed journal published by Elsevier Science London, focusing on the dynamic fields of Oncology and Radiology, Nuclear Medicine, and Imaging. With an impressive impact factor reflecting its high-quality research contributions, the journal is ranked in the second quartile for oncology and the first quartile for radiology, underscoring its importance in advancing clinical knowledge and practice. Established in 1975, Clinical Oncology offers researchers, healthcare professionals, and students robust access to cutting-edge studies, reviews, and clinical trials that drive innovation and improve patient care. Based in the United Kingdom, the journal plays a vital role in disseminating significant findings, fostering collaboration, and enhancing education in the biosciences, particularly for those committed to addressing the challenges in cancer treatment and diagnostics. Given its rigorous selection criteria and broad readership, Clinical Oncology remains an essential resource for anyone dedicated to the fields of oncology and radiology.

Translational Oncology

Pioneering the Next Generation of Cancer Treatments
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

CURRENT PROBLEMS IN CANCER

Advancing Oncology: Addressing Today’s Challenges in Cancer Research
Publisher: MOSBY-ELSEVIERISSN: 0147-0272Frequency: 6 issues/year

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

World Journal of Clinical Oncology

Uniting Global Experts in Clinical Oncology
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Surgical Oncology Clinics of North America

Innovative Insights for Surgical Excellence
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 1055-3207Frequency: 4 issues/year

Surgical Oncology Clinics of North America, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of surgical oncology and surgery, captivating readers since its inception in 1995. With ISSN 1055-3207 and E-ISSN 1558-5042, this esteemed journal offers a comprehensive platform for the dissemination of cutting-edge research, clinical studies, and expert reviews pertaining to surgical techniques and oncological advancements. The journal currently holds a commendable Q3 ranking in Oncology and a Q2 ranking in Surgery, underpinned by its impressive Scopus rankings that place it in the top 25% of its category in Medicine, particularly in the surgical domain (Rank #137/551). Although it does not operate under an open-access model, the insights shared within its pages are invaluable for researchers, healthcare professionals, and students dedicated to enhancing patient outcomes in surgical oncology. With a commitment to advancing medical knowledge, Surgical Oncology Clinics of North America remains a crucial resource for those pursuing excellence in surgical practices and oncology treatment methodologies.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pioneering critical insights in oncology and hematology.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

International Journal of Clinical Oncology

Pioneering Discoveries in Clinical Oncology
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

ACTA ONCOLOGICA

Shaping the future of cancer treatment and research.
Publisher: Medical Journal Sweden ABISSN: 0284-186XFrequency: 12 issues/year

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

Onkologie

Shaping the Future of Oncology Through Scholarly Dialogue.
Publisher: SPRINGER HEIDELBERGISSN: 2731-7226Frequency: 12 issues/year

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.